Andrew Fein, an analyst from H.C. Wainwright, maintained the Buy rating on Alector. The associated price target remains the same with $10.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Andrew Fein has given his Buy rating due to a combination of factors that highlight Alector’s promising position in the biotech sector. The upcoming INFRONT-3 trial readout for latozinemab in FTD-GRN is a significant catalyst, with strong biomarker and MRI signals suggesting a reduced risk and multiple regulatory pathways, including the possibility of accelerated approval. This pivotal readout is expected in the fourth quarter of 2025 and could provide substantial upside for investors.
Additionally, Alector’s diversified pipeline, which includes programs targeting Alzheimer’s, Parkinson’s, and siRNA, positions the company as more than just a single asset story. The engagement with Key Opinion Leaders (KOLs) has reinforced confidence in the trial’s design and potential outcomes. Despite the small sample size in Phase 2, the trial showed robust increases in progranulin and stabilization of neurofilament light chain, lending credibility to the approach. The choice of co-primary endpoints aligns with FDA preferences, further supporting the regulatory acceptability and potential success of the trial.
Fein covers the Healthcare sector, focusing on stocks such as Alector, BioCryst, and United Therapeutics. According to TipRanks, Fein has an average return of 25.3% and a 52.75% success rate on recommended stocks.